Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk

Ibrutinib is the first clinically approved inhibitor of Bruton’s tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and...

Descripción completa

Detalles Bibliográficos
Autores principales: Stühlinger, Markus C., Weltermann, Ansgar, Staber, Philipp, Heintel, Daniel, Nösslinger, Thomas, Steurer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2019
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035304/
https://www.ncbi.nlm.nih.gov/pubmed/31414181
http://dx.doi.org/10.1007/s00508-019-1534-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035304/
https://www.ncbi.nlm.nih.gov/pubmed/31414181
http://dx.doi.org/10.1007/s00508-019-1534-1

Ejemplares similares